Clinical trials: Cholangiocarcinomas
Primary Sclerosing Cholangitis (PSC)
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of…
- Trial name
- NCT03766035
- Testing
- SpyGlass DS I - II
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 43 people
- Sponsor
- Boston Scientific Corporation
Cholangiocarcinoma
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
This pilot trial will be used to assess the activity, safety and feasibility of doublet immunotherapy and platinum-based chemotherapy in resectable intrahepatic cholangiocarcinoma with high risk features.
- Trial name
- ICC (NCT04989218)
- Testing
- Novel combination of chemotherapy and immunotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in participants with locally advanced…
- Trial name
- NCT06501625
- Testing
- Ivosidenib, Durvalumab (for the first 8, 21-day, cycles), Gemcitabine (for the first 8, 21-day, cycles)
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 55 people
- Sponsor
- Institut de Recherches Internationales Servier
Intrahepatic Cholangiocarcinoma
Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma
To investigate the prognosis due to presence or absence of bile duct resection in intrahepatic cholangiocarcinoma that require hepatic lobectomy.
- Trial name
- NCT01862276
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Kansai Hepatobiliary Oncology Group
Intrahepatic Cholangiocarcinoma
TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection
- Trial name
- NCT02588755
- Testing
- TACE+Tegafur, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Advanced Intrahepatic Cholangiocarcinoma
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT.
- Trial name
- NCT06858735
- Testing
- Durvalumab, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Pancreatic Cancer
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Trial name
- NCT04421820
- Testing
- BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 220 people
- Sponsor
- Bold Therapeutics, Inc.
Intrahepatic Cholangiocarcinoma
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
This is a Phase III, prospective, randomized, three-arm, double-blind, placebo-controlled, international multicenter study to evaluate the efficacy and safety of toripalimab in combination with lenvatinib and gemcitabine-based…
- Trial name
- NCT05342194
- Testing
- Toripalimab, Lenvatinib mesylate capsules, Oxaliplatin for injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Biliary Carcinoma, Gall Bladder Carcinoma
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
The purpose of this study is to see if an experimental drug, called copanlisib is effective and safe in treating adult participants with cholangiocarcinoma, when used in combination with gemcitabine and cisplatin.
- Conditions
- Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma, Gastrointestinal Tumor
- Trial name
- NCT02631590
- Testing
- Cisplatin, Gemcitabine, Copanlisib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Malignant Neoplasm Other Gallbladder/Extrahepatic Bile Duct
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
The present study is designed to determine whether adjuvant concurrent chemoradiotherapy improves overall survivals.
- Trial name
- NCT02798510
- Testing
- Concurrent Chemoradiotherapy, capecitabine, gemcitabine
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Bladder Carcinoma, Cervical Carcinoma
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer.
- Conditions
- Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- FAPI PET RDRC (NCT04459273)
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Liver Cancer, Bile Duct Cancer
Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis
Only a small proportion of patients with biliary obstruction caused by hepatopancreatobiliary malignancies are suitable for surgical resection.
- Conditions
- Liver Cancer, Bile Duct Cancer, Pancreatic Cancer
- Trial name
- NCT02841800
- Testing
- 'Intra-luminal radiofrequency ablation (Habib EndoHPB)
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Adverse Drug Event, Colon Cancer
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
The purpose of this study is to examine the benefits of a clinical implementation of a DPYD-genotype test to patients starting treatment with fluoropyrimidines (Fluorouracil (5-FU), capecitabine, tegafur).
- Conditions
- Adverse Drug Event, Colon Cancer, Breast Cancer, Pancreas Cancer
- Trial name
- NCT05266300
- Testing
- DPYD genotype
- Where
- Denmark
- Volunteers
- 722 people
- Sponsor
- University of Southern Denmark
Intrahepatic Cholangiocarcinoma
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
This is a single center, single arm, phase II, prospective study to evaluate the safety and effectiveness of HAIC combined with TAE plus an ICI and an TKI in adult patients (aged ≥18 years) with unresectable intrahepatic…
- Trial name
- NCT06239532
- Testing
- HAIC+TAE, Tislelizumab, Surufatinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Qilu Hospital of Shandong University
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Hepatocholangiocarcinoma, Fibrolamellar Carcinoma
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy…
- Conditions
- Hepatocholangiocarcinoma, Fibrolamellar Carcinoma, Hepatic Epithelioid Hemangioendothelioma, Hepatoblastoma
- Trial name
- FFCD-2205 (NCT06541652)
- Where
- 40 sites in France
- Volunteers
- 150 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
- Trial name
- NCT06777316
- Testing
- CGT4859
- Where
- 13 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Cogent Biosciences, Inc.
Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma
Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy
The FIBROPANC-1 investigates the feasibility and safety of preoperative stereotactic radiotherapy of 4cm pancreas in patients undergoing pancreatoduodenectomy at high risk (>25%) of developing post operative pancreatic fistula…
- Conditions
- Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma, Pancreas Neoplasm, Distal Cholangiocarcinoma
- Trial name
- FIBROPANC-1 (NCT05641233)
- Testing
- Stereotactic radiotherapy
- Where
- 2 sites in Netherlands
- Volunteers
- 33 people
- Sponsor
- Erasmus Medical Center
Hepatocellular Cancer, Cholangiocarcinoma
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
PLATON (Platform for Analyzing Targetable Mutations) is a prospective, multicentre, observational cohort study with biobanking. In a first approach PLATON's pilot-study assesses genomic profiling in gastrointestinal cancer…
- Conditions
- Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- PLATON (NCT04484636)
- Testing
- FoundationOne®CDx and FoundationOne®Liquid
- Where
- 46 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Cancer, Metastatic Cancer
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Biliary Tract Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03027284
- Testing
- Merestinib, Cisplatin, Gemcitabine
- Where
- 2 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.